Elanco raises its outlook as innovation lifts both pet and farm-animal demand

28/08/2026

Elanco’s second-quarter results offer a more useful reading of the animal-health economy than a change of ownership: growth was visible in both companion animals and food production, and the company raised its full-year outlook while improving its leverage target. For commercial teams, suppliers and investors, the combination matters because it points to demand being supported by innovation, price and volume rather than by one narrow category alone.

Second-quarter revenue reached $1.368 billion, up 10% year on year, or 8% on an organic constant-currency basis. Adjusted EBITDA was $288 million, with a 21.2% margin, while the net leverage ratio stood at 3.1 times adjusted EBITDA. Elanco increased its full-year revenue guidance to $5.09 billion to $5.14 billion and lifted its adjusted EBITDA range to $1.01 billion to $1.035 billion. Its innovation-revenue target also rose to $1.25 billion.

The mix is especially relevant for an animal-health and nutrition audience. US Pet Health and US Farm Animal each grew 11% organically in constant currency. Farm-animal revenue was $633 million, up 9% reported and 5% organically; cattle revenue rose 17% reported, or 12% organically, while poultry increased 4% reported. Elanco described global ruminants as its fastest-growing species group, up 12% organically, supported by its beef and dairy portfolio. Pet Health revenue was $718 million, up 12% reported and 11% organically.

The underlying business takeaway is that portfolio breadth has strategic value when growth drivers are not identical. Elanco’s farm-animal performance gives the company exposure to protein-production economics, while companion-animal launches are supporting clinic demand and margin mix. The raised outlook is management guidance, not a guarantee. Still, the results provide a concrete signal that innovation investment, commercial execution and a balanced species portfolio can reinforce financial flexibility in a more disciplined animal-health market.